Lymphoma prognostic methods and kits

US2017081726A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2017081726-A1
Application numberUS-201615268938-A
CountryUS
Kind codeA1
Filing dateSep 19, 2016
Priority dateJun 22, 2012
Publication dateMar 23, 2017
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This disclosure describes, in one aspect, a method that, in general, includes analyzing a tumor tissue sample from a subject for expression of at least two biomarkers, wherein a predetermined ratio of expression of the at least two biomarkers identifies the tumor tissue sample as coming from a subject having a particular subtype of lymphoma; and identifying the subject as having a particular subtype of lymphoma.

First claim

Opening claim text (preview).

1 - 25 . (canceled) 26 . A kit for determining prognosis of a subject, the kit comprising: reagents for measuring expression of a plurality of predictive coding regions in a sample from the subject, the plurality of predictive coding regions comprising at least one of: a combination of CD28 and ABCA5; or a combination of CCDC3 and SMOC2. 27 . The kit of claim 26 wherein the reagents for measuring expression of a plurality of predictive coding regions comprises reagents for performing Northern blotting, nuclease protection assay, DNA microarray, serial analysis of gene expression, quantitative reverse transcription-polymerase chain reaction (RT-PCR), differential-display RT-PCR, massively parallel signature sequencing, or real-time quantitative PCR. 28 . The kit of claim 26 wherein the reagents for measuring expression of a plurality of predictive coding regions comprises reagents for performing protein expression analysis. 29 - 34 . (canceled)

Assignees

Inventors

Classifications

  • Prognosis of disease development · CPC title

  • acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase · CPC title

  • attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

  • Amides of phosphorus acids · CPC title

  • Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2017081726A1 cover?
This disclosure describes, in one aspect, a method that, in general, includes analyzing a tumor tissue sample from a subject for expression of at least two biomarkers, wherein a predetermined ratio of expression of the at least two biomarkers identifies the tumor tissue sample as coming from a subject having a particular subtype of lymphoma; and identifying the subject as having a particular su…
Who is the assignee on this patent?
Univ Minnesota
What technology area does this patent fall under?
Primary CPC classification C12Q1/6886. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Mar 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).